Victor S. Sloan - Concepedia

Author

Victor S. Sloan

Also Known As

David Yocum, V S Sloan, V Sloan, V. S. Sloan, V. Sloan, V.S. Sloan, Victor S. Sloan, Victor S Sloan, Victor S. Sloan, Victor Schorr Sloan

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)Rutgers, The State University of New Jersey Johnson University University of Ottawa

About

Victor S. Sloan is an author at Novartis (United States) specializing in medicine, pharmacotherapy, and osteoarthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	359
2	Engineering	1	1	24
3	Public Health	1	1	30
4	Allergy	1	1	163
5	Biochemistry	1	1	543

Victor S. Sloan

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Mediation by HLA-DM of dissociation of peptides from HLA-DR Victor S. Sloan, Patricia M. Cameron, Gene Porter, Nature Protein FoldingPeptide LibraryBiochemistryPeptide Synthesis	1995	543
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases Georg Schett, Victor S. Sloan, Randall M. Stevens, Therapeutic Advances in Musculoskeletal Disease Phosphodiesterase 4ImmunologyCell DeathBiological TherapyImmunotherapy	2010	163
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis Stephen Jarrett, Philip G. Conaghan, Victor S. Sloan, Arthritis & Rheumatism	2006	152
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib R. Lehmann, Marek Brzosko, Petr Kopsa, Current Medical Research and Opinion	2005	73
Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo Eric Sheldon, André Beaulieu, Zorba Paster, Clinical Therapeutics MedicineChronic Musculoskeletal ConditionOsteoarthritisNon-operative ManagementPharmacotherapy	2005	63
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial Thomas J. Schnitzer, Jannie Beier, Piet Geusens, Arthritis Care & Research	2004	55
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib Roy Fleischmann, Eric Sheldon, José A. Maldonado‐Cocco, Clinical Rheumatology MedicineChronic Musculoskeletal ConditionOsteoarthritisInflammatory Rheumatic DiseasePharmacotherapy	2005	46
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis Piet Geusens, Rieke Alten, Jozef Rovenský, International Journal of Clinical Practice	2004	40
Risk of <scp>QT</scp> prolongation and torsade de pointes associated with exposure to hydroxyzine: re‐evaluation of an established drug Anne‐Françoise Schlit, Annie Delaunois, Aurore Colomar, Pharmacology Research & Perspectives	2017	36
Zidovudine therapy in an inner city population. Jonathan E. Samuels, Josephine Hendrix, Madeline Hilton, PubMed Primary ImmunodeficiencyAcceptable ComplianceEpidemiologyTreatment And PreventionZidovudine Therapy	1990	30

Page 1